GlaxoSmithKline is a major biopharmaceutical company that develops and sells medicines and vaccines. Its filings show it lobbied Congress mainly on Medicare and Medicaid matters, especially implementation of the Inflation Reduction Act of 2022 (H.R.5376) and related drug pricing provisions. It used W Strategies, LLC and reported $160,000 across four filings through January 20, 2026.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
DARREN WILLCOX
The latest disclosures for this client.
W STRATEGIES, LLC
Q1W STRATEGIES, LLC
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
W STRATEGIES, LLC
W STRATEGIES, LLC
Q3W STRATEGIES, LLC
Q2W STRATEGIES, LLC
Q1